Fisher Asset Management LLC Has $14.24 Million Stock Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Fisher Asset Management LLC boosted its stake in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 125.8% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 204,672 shares of the company's stock after acquiring an additional 114,022 shares during the period. Fisher Asset Management LLC owned 0.12% of Dr. Reddy's Laboratories worth $14,241,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC acquired a new stake in shares of Dr. Reddy's Laboratories during the fourth quarter worth $34,000. CWM LLC boosted its position in shares of Dr. Reddy's Laboratories by 37.9% during the fourth quarter. CWM LLC now owns 2,174 shares of the company's stock worth $151,000 after buying an additional 598 shares during the period. Blue Trust Inc. boosted its position in shares of Dr. Reddy's Laboratories by 77.3% during the fourth quarter. Blue Trust Inc. now owns 3,378 shares of the company's stock worth $227,000 after buying an additional 1,473 shares during the period. Lindbrook Capital LLC boosted its position in shares of Dr. Reddy's Laboratories by 19.1% during the fourth quarter. Lindbrook Capital LLC now owns 3,519 shares of the company's stock worth $245,000 after buying an additional 565 shares during the period. Finally, Advisors Preferred LLC acquired a new position in shares of Dr. Reddy's Laboratories during the fourth quarter worth approximately $258,000. Institutional investors and hedge funds own 14.02% of the company's stock.

Dr. Reddy's Laboratories Stock Down 0.4 %

Shares of RDY stock traded down $0.33 during trading on Monday, hitting $74.88. 163,886 shares of the company were exchanged, compared to its average volume of 195,152. The business's 50-day simple moving average is $73.93 and its 200 day simple moving average is $70.80. Dr. Reddy's Laboratories Limited has a twelve month low of $53.12 and a twelve month high of $77.72. The firm has a market capitalization of $12.50 billion, a price-to-earnings ratio of 19.76, a P/E/G ratio of 1.88 and a beta of 0.57. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.90 and a current ratio of 2.55.

Analysts Set New Price Targets

Several brokerages recently commented on RDY. Barclays boosted their target price on Dr. Reddy's Laboratories from $75.00 to $80.00 and gave the stock an "overweight" rating in a report on Monday, January 29th. Jefferies Financial Group cut Dr. Reddy's Laboratories from a "buy" rating to an "underperform" rating in a report on Thursday, January 11th. Finally, StockNews.com cut Dr. Reddy's Laboratories from a "strong-buy" rating to a "buy" rating in a report on Tuesday, April 30th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Dr. Reddy's Laboratories presently has an average rating of "Hold" and a consensus price target of $80.00.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.